Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 2% CP-690,550 QD | Experimental |
| |
| 0.2% CP-690,550 QD | Experimental |
| |
| 0.02% CP-690,550 QD | Experimental |
| |
| 2% CP-690,550 BID | Experimental |
| |
| 0.2% CP-690,550 BID | Experimental |
| |
| 0.02% CP-690,550 BID | Experimental |
| |
| Placebo Vehicle QD | Placebo Comparator |
| |
| Placebo Vehicle BID | Placebo Comparator |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CP-690,550 | Drug | Topical treatment once daily for 28 days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 | TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point severity scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease. | Baseline, Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Success Based on Physician's Global Assessment (PGA) of Target Lesions | PGA of Psoriasis: The investigator scored each target lesion on a 5-point scale, reflecting the erythema, induration and scaling separately for each target lesions. Each parameter was scored from 0 to 4, with appropriate morphologic descriptors. The 5-point scale for PGA was: 0, "clear"; 1, "almost clear"; 2, "mild"; 3, "moderate"; 4 "severe". The sum of the 3 scores was divided by 3 to obtain a final PGA score. Total score range: 0 to 4, higher score indicated greater severity of disease. Success was considered as PGA response of "clear" and "almost clear". |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California Irvine | Irvine | California | 92697 | United States | ||
| Therapeutics Clinical Research |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26267721 | Derived | Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. J Drugs Dermatol. 2015 Aug;14(8):777-84. |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
During the study, enrollment into the 4 once daily dosing regimen treatment groups was discontinued in order to decrease the overall total number of participants to be enrolled.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 2% CP-690,550 Once Daily | CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| FG001 | 0.2% CP-690,550 Once Daily |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| CP-690,550 |
| Drug |
Topical treatment once daily for 28 days |
|
| CP-690,550 | Drug | Topical treatment once daily for 28 days |
|
| CP-690,550 | Drug | Topical treatment twice daily for 28 days |
|
| CP-690,550 | Drug | Topical treatment twice daily for 28 days |
|
| CP-690,550 | Drug | Topical treatment twice daily for 28 days |
|
| Placebo Vehicle | Drug | Topical treatment once daily for 28 days |
|
| Placebo Vehicle | Drug | Topical treatment twice daily for 28 days |
|
| Week 4 |
| Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 1, 2 and 3 | TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease. | Baseline, Week 1, 2, 3 |
| Number of Participants With Administration Site Adverse Events | An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Administration site adverse event included documentation of any clinically significant local reaction, such as erosion, vesicles or scabbing. | Baseline up to 7 to 10 days after last dose of study treatment (maximum up to 38 days) |
| Drug Plasma Concentrations of CP-690,555 | Concentrations below the limit of quantification (LOQ) were not estimable. The LOQ was 0.1 ng/mL. | 0 hour (pre-dose) on Day 14 and 0 hour (pre-dose), 1, 2, 9 hours post-dose on Day 28 |
| Skin Biopsy Drug Concentrations | Skin biopsy drug concentrations was measured via drug levels in dermis and expressed as nanogram of drug per milligram (mg) of dermis weight. Tissue concentration (ng/mg) = (ng drug/mL extraction solvent multiplied by mL extraction solvent) divided by mg tissue weight; 1 mL of extraction solvent was used. | Day 28 |
| San Diego |
| California |
| 92123 |
| United States |
| RUSH University Medical Center | Chicago | Illinois | 60612 | United States |
| Tufts Medical Center | Boston | Massachusetts | 02111 | United States |
| University of Michigan | Ann Arbor | Michigan | 48109-0314 | United States |
| Minnesota Clinical Study Center | Fridley | Minnesota | 55432-3134 | United States |
| Central Dermatology, PC | St Louis | Missouri | 63117 | United States |
| Dermatology Consulting Services | High Point | North Carolina | 27262 | United States |
| The Imaging Center | High Point | North Carolina | 27262 | United States |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | United States |
| Oregon Medical Research Center, PC | Portland | Oregon | 97223 | United States |
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
| DermResearch, Inc. | Austin | Texas | 78759 | United States |
| University of Utah School of Medicine | Salt Lake City | Utah | 84132 | United States |
| Guildford Dermatology Specialists | Surrey | British Columbia | V3R 6A7 | Canada |
| NewLab Clinical Research Inc. | St. John's | Newfoundland and Labrador | A1C 2H5 | Canada |
| K.Papp Clinical Research Inc. | Waterloo | Ontario | N2J 1C4 | Canada |
| Innovaderm Research, Inc. | Montreal | Quebec | H2K 4L5 | Canada |
| Siena Medical Research | Montreal | Quebec | H3Z 2S6 | Canada |
| Centre de Recherche Dermatologique du Quebec metropolitain | Québec | Quebec | G1V 4X7 | Canada |
CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| FG002 | 0.02% CP-690,550 Once Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| FG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. |
| FG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| FG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| FG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| FG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 2% CP-690,550 Once Daily | CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| BG001 | 0.2% CP-690,550 Once Daily | CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| BG002 | 0.02% CP-690,550 Once Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| BG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. |
| BG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| BG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| BG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| BG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. |
| BG008 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 | TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point severity scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease. | Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy parameter. N (number of participants analyzed) is signifying those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | Percent Change | Baseline, Week 4 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Success Based on Physician's Global Assessment (PGA) of Target Lesions | PGA of Psoriasis: The investigator scored each target lesion on a 5-point scale, reflecting the erythema, induration and scaling separately for each target lesions. Each parameter was scored from 0 to 4, with appropriate morphologic descriptors. The 5-point scale for PGA was: 0, "clear"; 1, "almost clear"; 2, "mild"; 3, "moderate"; 4 "severe". The sum of the 3 scores was divided by 3 to obtain a final PGA score. Total score range: 0 to 4, higher score indicated greater severity of disease. Success was considered as PGA response of "clear" and "almost clear". | FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. N (number of participants analyzed) is signifying those participants who were evaluable for this measure. | Posted | Number | Percentage of Participants | Week 4 |
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 1, 2 and 3 | TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease. | FAS: all randomized participants who received at least 1 dose of study medication; had a valid baseline with at least 1 valid post-baseline efficacy assessment. Here 'N' (number of participants analyzed)= participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, Week 1, 2, 3 |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Administration Site Adverse Events | An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Administration site adverse event included documentation of any clinically significant local reaction, such as erosion, vesicles or scabbing. | FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. | Posted | Count of Participants | Participants | Baseline up to 7 to 10 days after last dose of study treatment (maximum up to 38 days) |
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Drug Plasma Concentrations of CP-690,555 | Concentrations below the limit of quantification (LOQ) were not estimable. The LOQ was 0.1 ng/mL. | FAS: all randomized participants who received at least 1 dose of study medication; had a valid baseline with at least 1 valid post-baseline efficacy assessment of CP-690,550. Participants of reporting groups 2%, 0.2% and 0.02% CP-690,550 Once Daily regimen had no post-baseline measurable concentration of CP-690,550. "Overall number of participants analyzed" = who were evaluable for this measure. | Posted | Mean | Standard Deviation | nanogram per milliliter (ng/mL) | 0 hour (pre-dose) on Day 14 and 0 hour (pre-dose), 1, 2, 9 hours post-dose on Day 28 |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Skin Biopsy Drug Concentrations | Skin biopsy drug concentrations was measured via drug levels in dermis and expressed as nanogram of drug per milligram (mg) of dermis weight. Tissue concentration (ng/mg) = (ng drug/mL extraction solvent multiplied by mL extraction solvent) divided by mg tissue weight; 1 mL of extraction solvent was used. | FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. Overall number of participants analyzed = participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | ng/mg | Day 28 |
|
Not provided
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 2% CP-690,550 Once Daily | CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. | 0 | 6 | 4 | 6 | ||
| EG001 | 0.2% CP-690,550 Once Daily | CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. | 0 | 6 | 2 | 6 | ||
| EG002 | 0.02% CP-690,550 Once Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. | 0 | 8 | 5 | 8 | ||
| EG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. | 0 | 4 | 3 | 4 | ||
| EG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. | 0 | 17 | 6 | 17 | ||
| EG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. | 0 | 17 | 11 | 17 | ||
| EG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. | 0 | 15 | 7 | 15 | ||
| EG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. | 0 | 8 | 4 | 8 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lymphadenopathy | Blood and lymphatic system disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Lymphopenia | Blood and lymphatic system disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Application site irritation | General disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Application site pruritus | General disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Chest discomfort | General disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Folliculitis | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Hordeolum | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Pharyngitis streptococcal | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Tooth infection | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Sunburn | Injury, poisoning and procedural complications | MedDRA v12.0 | Non-systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Blood bilirubin increased | Investigations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Blood triglycerides increased | Investigations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Cardiac murmur | Investigations | MedDRA v12.0 | Non-systematic Assessment |
| |
| Hyperlipidaemia | Metabolism and nutrition disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Adjustment disorder with depressed mood | Psychiatric disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Pollakiuria | Renal and urinary disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Photosensitivity reaction | Skin and subcutaneous tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
| |
| Skin irritation | Skin and subcutaneous tissue disorders | MedDRA v12.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C479163 | tofacitinib |
Not provided
Not provided
Not provided
| Male |
|
| OG002 | 0.02% CP-690,550 Once Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| OG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. |
| OG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. |
|
|
| 0.02% CP-690,550 Once Daily |
CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28. |
| OG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. |
| OG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. |
|
|
| OG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. |
| OG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. |
|
|
|
|
| OG003 | Placebo Once Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28. |
| OG004 | 2% CP-690,550 Twice Daily | CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG005 | 0.2% CP-690,550 Twice Daily | CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG006 | 0.02% CP-690,550 Twice Daily | CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28. |
| OG007 | Placebo Twice Daily | CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28. |
|
|